Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05471206
Other study ID # 2021-A02653-38
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 24, 2022
Est. completion date February 15, 2024

Study information

Verified date March 2024
Source Lactalis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study is designed as a monocentric, open label, interventional, parallel arms, controlled clinical trial. The aim of the study is to assess the gastrointestinal pH and motility after the consumption of milk. The clinical study is categorized as an interventional research involving the human person with low risks and constraints (RIPH 2) and which does not assess a health product. The milk and medical device used in this clinical study are both authorized and already commercialized in France.


Recruitment information / eligibility

Status Terminated
Enrollment 28
Est. completion date February 15, 2024
Est. primary completion date February 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Age between 18 and 40 years (limits included), - BMI between 18.5 and 30 kg/m² (limits included), - Able and willing to drink 250mL of milk in 5 minutes, - Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or clinical examination, - Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form, - Affiliated with a social security scheme, - For milk intolerant subjects: self-reporting symptoms after drinking milk and drinking less than 150mL of cow's milk (lactose-free milk not included) per week (assessed by the gastrointestinal symptoms questionnaire filled out at V0). - For milk tolerant subjects: drinking at least 700mL of cow's milk (lactose-free milk not included) per week (assessed by the gastrointestinal symptoms questionnaire filled out at V0). Exclusion Criteria: - Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble, uncontrolled arterial hypertension or other metabolic disorder, - Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis, etc.) or disorders found to be inconsistent with the conduct of the study by the investigator, - Suffering from any obstructive or restrictive respiratory syndrome (COPD, asthma, etc.) that may impact breath test measurements, - Suffering from a gastro-intestinal pathology (inflammatory bowel disease, Crohn disease, ulcerative colitis, irritable bowel syndrome, celiac disease, gluten hypersensitivity, small intestinal bacterial overgrowth, diverticulitis, polyps, constipation, esophageal motility abnormality, history of gastric bezoar...), or other gastro-intestinal disorders found to be inconsistent with the conduct of the study by the investigator, - Suffering from any disorder found to be inconsistent with the conduct of the study by the investigator, - With a history of gastro-intestinal surgery (only appendectomy is accepted), - With swallowing problems, - With a known or suspected allergy to cows' milk protein, - With a lactose intolerance diagnosed by a positive Lactose Breath Test, - Pregnant or lactating women or intending to become pregnant during the study, - Under treatment or dietary supplement which could significantly affect the gut motility and/or interfere with gastric emptying time and/or affect the gut pH during the study according to the investigator or stopped less than 15 days before the V0 visit (examples: NSAIDs, proton pump inhibitors, prokinetics, treatments against diarrhea or constipation, etc.), - Regular intake of dietary supplements containing prebiotics, probiotics or symbiotics, or stopped less than 3 months before the V0 visit, - With significant change in food habits or in physical activity in the 3 months before the V0 visit or not agreeing to keep them unchanged throughout the study, - Weight loss or gain > 5% of body weight in the 6 months before the study, - With a current diet or stopped less than 3 months before the study, - With a current eating disorder (anorexia nervosa, bulimia, etc.) according to the investigator, - Consuming more than 2 standard drinks of alcoholic beverage daily regularly and not agreeing to keep alcohol consumption habits unchanged throughout the study, - Smoker (electronic cigarette not allowed), - Consuming illicit drugs, - Having an implanted or portable electro-mechanical medical device (such as pacemakers, defibrillators, infusion pumps…etc), - Taking part in another clinical trial or being in the exclusion period of a previous clinical trial, - Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision, - Presenting a psychological or linguistic incapability to sign the informed consent, - Impossible to contact in case of emergency.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Milk and SmartPill intakes
During visit V2, the subject will ingest the SmartPill capsule. Then, subjects will drink milk.

Locations

Country Name City State
France CHU Rennes Rennes

Sponsors (2)

Lead Sponsor Collaborator
Lactalis BioFortis

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint in this study is the AUC of pH, defined between 0 and 120 minutes after ingestion of milk, expressed in pH.min. 2 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1